Published date: Oct 01 2019

Journal Title: International Journal of Reproductive BioMedicine

Issue title: International Journal of Reproductive BioMedicine (IJRM): Volume 17, Issue No. 10

Pages:

DOI: 10.18502/ijrm.v17i10.5296

Afsane GhasemiShahid Akbar Abadi Hospital Clinical Research Development Unit (ShACRDU), Iran University of Medical Sciences (IUMS), Tehran, Iran

Fatemehsadat AmjadiCellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran; Department of Anatomical Sciences, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Seyedeh Masoumeh Ghazi Mirsaeeddr.ghazi83@gmail.comShahid Akbar Abadi Hospital Clinical Research Development Unit (ShACRDU), Iran University of Medical Sciences (IUMS), Tehran, Iran

Robabeh Mohammad BeigiShahid Akbar Abadi Hospital Clinical Research Development Unit (ShACRDU), Iran University of Medical Sciences (IUMS), Tehran, Iran

Samaneh GhasemiShahid Akbar Abadi Hospital Clinical Research Development Unit (ShACRDU), Iran University of Medical Sciences (IUMS), Tehran, Iran

Yousef MoradiDepartment of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran

Seyedeh Tahereh Ghazi MirsaeedShahid Akbar Abadi Hospital Clinical Research Development Unit (ShACRDU), Iran University of Medical Sciences (IUMS), Tehran, Iran

Background: In about 40% of the couples, the cause of infertility problems is attributed to men because of low sperm production and disturbed motility of sperm. Pieces of evidence show that Myo-inositol has a potential role for the treatment of sperm morphology and male fertility.

Objectives: This study aimed to determine the effect of Myo-inositol on the sperm parameters and fertility rate in patients with oligoasthenospermia treated by intrauterine insemination (IUI).

Materials and Methods: This study was a randomized clinical trial conducted on 37 patients with oligoasthenospermia treated by IUI during 2016-2017. In this study, the patients were randomly divided into two groups of oligoasthenospermia treated with (Case group) and without Myo-inositol (Control group). The case group received 0.5 ml of Myo-inositol with a concentration of 2 mg/ml and incubated at 37°C incubator for 2 hr, but the control group had no interventions.

Results: The results of this study showed that although there was no significant difference in sperm parameters including sperm motility and concentration before processing with Myo-inositol in the case group, but there was a significant increase in sperm motility during the treatment with Myo-inositol. The therapeutic effect of this method was confirmed on induction of pregnancy in 18% of the treated patients, in such a way that was about twice greater than those who did not receive the drug.

Conclusion: According to the results of this study, the use of Myo-inositol is efficient enough to change sperm parameters to increase the chance of fertility.

Key words: Myo-inositol, Pregnancy, Sperm, Motility, Oligoasthenospermic.

[1] Diaz JR, De Las Cagigas A, Rodriguez R. Micronutrient deficiencies in developing and affluent countries. Eur J Clin Nutr 2003; 57 (Suppl.): S70–72.

[2] Stachecki JJ, Armant DR. Transient release of calcium from inositol 1, 4, 5-trisphosphate-specific stores regulates mouse preimplantation development. Development 1996; 122: 2485–2496.

[3] Beemster P, Groenen P, Steegers−Theunissen R. Involvement of inositol in reproduction. Nutr Rev 2002; 60: 80–87.

[4] Ciotta L, Stracquadanio M, Pagano I, Carbonaro A, Palumbo M, Gulino F. Effects of myo-inositol supplementation on oocyte’s quality in PCOS patients: a double blind trial. Eur Rev Med Pharmacol Sci 2011; 15: 509–514.

[5] Ortmeyer HK. Dietary myoinositol results in lower urine glucose and in lower postprandial plasma glucose in obese insulin-resistant rhesus monkeys. Obes Res 1996; 4: 569–575.

[6] Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol 2007; 23: 700–703.

[7] Hinton BT, White RW, Setchell BP. Concentrations of myoinositol in the luminal fluid of the mammalian testis and epididymis. J Reprod Fertil 1980; 58: 395–399.

[8] Colone M, Marelli G, Unfer V, Bozzuto G, Molinari A, Stringaro A. Inositol activity in oligoasthenoteratospermia– an in vitro study. Eur Rev Med Pharmacol Sci 2010; 14: 891– 896.

[9] Liu DY, Clarke GN, Baker HW. Hyper-osmotic condition enhances protein tyrosine phosphorylation and zona pellucida binding capacity of human sperm. Hum Reprod 2005; 21: 745–752.

[10] Cryns K, Shamir A, Van Acker N, Levi I, Daneels G, Goris I, et al. IMPA1 is essential for embryonic development and lithium-like pilocarpine sensitivity. Neuropsychopharmacology 2008; 33: 674–684.

[11] Martínez-Heredia J, de Mateo S, Vidal-Taboada JM, Ballesca JL, Oliva R. Identification of proteomic differences in asthenozoospermic sperm samples. Hum Reprod 2008; 23: 783–791.

[12] Speroff L, Fritz MA. Clinical gynecologic endocrinology and infertility. London; lippincott Williams & wilkins: 2005.

[13] Barratt CL, Mansell S, Beaton C, Tardif S, Oxenham SK. Diagnostic tools in male infertility-the question of sperm dysfunction. Asian J Androl 2011; 13: 53–58.

[14] Tomlinson M, Lewis S, Morroll D, British Fertility Society. Sperm quality and its relationship to natural and assisted conception: British Fertility Society Guidelines for practice. Hum Fertil 2013; 16: 175–193.

[15] van der Steeg JW, Steures P, Eijkemans MJ, F Habbema JD, Hompes PG, Kremer JA, et al. Role of semen analysis in subfertile couples. Fertil Steril 2011; 95: 1013–1019.

[16] Chauvin TR, Griswold MD. Characterization of the expression and regulation of genes necessary for myo-inositol biosynthesis and transport in the seminiferous epithelium. Biol Reprod 2004; 70: 744–751.